Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer
Valeant Pharmaceuticals International, Inc. announced today that Robert L. Rosiello was appointed as Executive Vice President and will take over the role of Chief Financial Officer on July 1, 2015.
June 11, 2015
Valeant Pharmaceuticals International, Inc.
(NYSE: VRX) (TSX: VRX) announced today that
Robert L. Rosiello
was appointed as Executive Vice President and will take over the role of Chief Financial Officer from
, 2015. Mr. Schiller will remain on Valeant's Board and is expected to serve as a consultant to Valeant.
"The Board of Directors and I are delighted that Rob has agreed to join Valeant," said
J. Michael Pearson
, Chairman and Chief Executive Officer. "Rob is someone I have worked closely with for 20 years. I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our Board of Directors."
Mr. Rosiello worked 30 years at
McKinsey & Company
helping healthcare, technology and consumer companies deliver growth through M&A and business unit financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S.,
Mr. Rosiello serves on the Board of
Catholic Charities of New York
Pew Research Center
Central Selection Committee
Morehead Cain Foundation
. He received his BA in economics from the
University of North Carolina
, where he was a Morehead Scholar. He also earned an MS from the
London School of Economics
and an MBA from